WACO, Texas, Nov. 24, 2003 (PRIMEZONE) -- Health Discovery Corporation (OTCBB:HDVY), formerly Direct Wireless Communications, Inc., a biotechnology company which is focused on biomarker and pathway discovery for diagnostic markers and drug targets, today announced the appointment of Dr. Isabelle Guyon to its Scientific Advisory Board.
Dr. Guyon is an internationally recognized expert in statistical data analysis, pattern recognition and machine learning. She is an acknowledged leader in her field serving as an expert with the European Commission to review grant proposals, as well as, Vice-President of the International Unipen Foundation.
Since 1996 when she started her consulting practice, Clopinet, Dr. Guyon has worked on projects for both small and large companies, including the design and implementation of a program to teach cursive handwriting to children, a fingerprint verification system, and bioinformatics data analysis methods for genomics and proteomics applications in biomarker discovery.
Prior to 1996, Dr. Guyon held a Principal Investigator research position at AT&T Bell Laboratories for six years. While at AT&T Bell Laboratories, she pioneered applications of neural networks to handwriting recognition for pen computers. In addition, while collaborating with Bernhard Boser and Vladimir Vapnik, she invented the Support Vector Machine method of data classification, which has become an internationally validated reference textbook method of machine learning, which is currently used in drug and diagnostic biomarker discovery worldwide.
Dr. Guyon holds a Ph.D. degree in Physical Sciences of the University Pierre and Marie Curie of Paris, France and is an engineer of the school of Physics and Chemistry of Paris.
"It is wonderful news that Dr. Isabelle Guyon, with her industry wide experience and expertise in machine learning and biomarker discovery, her abundant energy and enthusiasm, and expert data analysis skills, has agreed to become a member of our Scientific Advisory Board," said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "Adding Dr. Guyon to our team of Scientific Advisors significantly strengthens our expertise in biomarker discovery for diagnostic and pharmaceutical applications."
Dr. Isabelle Guyon commented, "The advent of high-throughput methods has revolutionized biomarker discovery and medical diagnosis but still poses major challenges to data analysis. Biologists are starting to acknowledge the power of machine learning, but few know how to harness this power. The team that Dr. Barnhill is assembling will be at the forefront of the applications of these new tools."
This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.